Press release

Medidata to Present Breakthrough Innovation at 2019 ASCO Annual Meeting

Sponsored by Businesswire

For the third consecutive year, Medidata
(NASDAQ: MDSO) will present breakthrough scientific findings at the
American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The joint poster presentation with the Friends
of Cancer Research
(Friends) will occur on June 2 at 8:00
a.m. – 11:00 a.m. CDT during the Lung Cancer – Non-Small Cell Metastatic

Medidata and Friends will present the poster 9108, Non-Small
Cell Lung Cancer (NSCLC) Case Study Examining Whether Results in a
Randomized Control Arm are Replicated by a Synthetic Control Arm (SCA)
which addresses:

  • The methodology for building a synthetic control arm based on high
    quality, cross-study, standardized clinical trial data from previous
    NSCLC studies
  • Research comparing the synthetic control arm to a randomized control
    group from an NSCLC trial
  • The potential for using synthetic control arms to augment or replace
    randomized controls in future clinical trials
  • The promise of intelligent trials, powered by machine learning and AI


  • Ruthie Davi, vice president, Acorn AI, a Medidata company
  • Mark Stewart, vice president, science policy, Friends of Cancer

“In collaboration with Friends, we have demonstrated that
using historical clinical trial data and analytical statistical methods
to create a synthetic control arm can significantly augment our
understanding about product performance. It is our expectation that, in
cases where a concurrent randomized control is not practicable, these
methodologies will help speed innovative products to patients,” said
Sastry Chilukuri, president, Acorn AI, a Medidata company.

Medidata will also demonstrate at booth #6147 in the Exhibit Hall:

  • Medidata Rave Clinical CloudTM: Optimize
    operational execution, decrease the data entry and maintenance burden,
    and reduce the number of clinical systems across study teams with a
    single source of truth for all oncology study-related data.
  • Acorn AI: Answer the most important questions in oncology
    across R&D and commercialization to improve outcomes for patients and
    accelerate digital transformation and growth for customers. Apply
    machine learning algorithms to drive timely decision on efficacy and
    safety during trial conduct. Seamlessly provide artificial
    intelligence as a service for a variety of clinical and commercial use
    cases, saving customers from developing similar AI solutions and
    enabling their data science teams to focus on higher value activities.
  • SHYFT: Conduct, design, and gain insight from outcomes-based
    observational research in hours rather than months. Drive converged
    intelligence across Epidemiology, HEOR, Pharmacovigilance, market
    research, corporate development, and commercial teams.

About Medidata

Medidata is leading the digital transformation of life sciences, with
the world’s most-used platform for clinical development, commercial, and
real-world data. Powered by artificial intelligence and delivered by the
top ranked industry experts, Medidata helps pharmaceutical, biotech,
medical device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata and its companies, Acorn
AI and SHYFT, serve more than 1,200 customers and partners worldwide and
empower more than 150,000 certified users every day to create hope for
millions of patients. Discover the future of life sciences:

About Friends of Cancer Research

Friends of Cancer Research (Friends) drives collaboration among
partners from every healthcare sector to power advances in science,
policy, and regulation that speed lifesaving treatments to patients. For
more information, please visit